Technology
Get in touch
THE FOUNDERS
Dr. Sol Cabrera
Dr. Bart Sanders
Latest News
It’s Time to #FundRight
Breaking the mold! STENTiT is proud to be highlighted as one of the 200 start-ups featured in the bid book: It’s time to #FundRight. With #FundRight, a large group of concerned and committed investors have taken the stance to address equal access to finance and opportunities for all founders, regardless of their background or gender.[…]
STENTiT Finalist in the TCT Shark Tank Competition
On Thursday September 27th, STENTiT will participate as one of the finalists in the Shark Tank Competition during the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. TCT is the annual scientific symposium organized by the Cardiovascular Research Foundation (CRF) and the world’s premier educational meeting specializing in interventional cardiovascular medicine. Now in its 31st[…]
Prince Constantijn and Miss Ivanka Trump award STENTiT for both Outstanding Woman Entrepreneur and GIST Health Runner-Up during the GES
During the Global Entrepreneurship Summit (GES), STENTiT proudly participated in the Global Innovation through Science & Technology (GIST) Catalyst pitch competition, organised in collaboration with the Dutch Academic Start-Up Competition. The GIST Catalyst competition began with over 4,000 applications from all over the world, which narrowed down to a list of top 30 companies giving[…]
STENTiT Selected to Pitch on Global Entrepreneurship Summit 2019
On Tuesday June 4th, STENTiT will be presenting during the Global Entrepreneurship Summit (GES) 2019 at the World Forum in The Hague. The presentation is part of the GIST Catalyst & Academic Olympics Pitch session held at 15:00 in the Europe room. The program provides Science & Technology entrepreneurs throughout the world with the opportunity[…]
STENTiT wins top ten list of most groundbreaking innovations in science
Stentit is one of the ten winners of the Academic Startup Competition. This was announced by a professional jury in Amsterdam in the presence of State Secretary for Economic Affairs and Climate, Mona Keijzer. As a result of the selection, Stentit will be able to pitch at the Global Entrepreneurship Summit (GES) and will be[…]
STENTiT Nominated for the Most Pioneering Innovations in Science
STENTiT has been nominated for the Academic Startup Competition 2019. Together with 26 other nominees, STENTiT is fighting for a place in the top ten of the most pioneering innovations of science in the Netherlands. The Academic Startup Competition is an initiative of VSNU, the Dutch Academy of Technology and Innovation (AcTI) and StartupDelta. The[…]
STENTiT’s Regenerative Stent Technology at ICI 2018 in Tel Aviv
STENTiT’s promising first in-vivo data will be presented at the premier international meeting for innovation in cardiovascular systems, ICI 2018 event in Tel Aviv, Israël. Dr. Yoshinobu Onuma MD PhD, from the Erasmus Medical Center of Rotterdam, will present STENTiT’s scientific evidence and clinical applications of the regenerative stent technology in the session; “Stents –[…]
Slash Magazine Interview with STENTiT
The current edition of Slash magazine features an interesting interview with the founders of STENTiT. In case you want to know more about the past, present and future of STENTiT, please have a look at the full article using the following link. Slash is the alumni- and relation magazine of the Eindhoven University of Technology.[…]
HRH Prince Constantijn highlights STENTiT among the 10 Dutch Breakthrough Technologies
This year at CES Unveiled Amsterdam, Special Envoy StartupDelta Constantijn van Oranje announced the 10 Dutch Breakthrough Technologies of 2018. Among the impressive list, STENTiT was proudly highlighted in the field of Regenerative Medicine. The list has been compiled in consultation with leading academics, investors and industry experts to showcase the next big dutch breakthrough[…]
STENTiT Receives EIT Health Funding
The health division from the European Institute of Innovation and Technology (EIT Health), provides financial support to STENTiT from the Headstart Funding Programme. The money is granted to support further product development and market validation of the regenerative stent. EIT Health provides funding for early stage companies and SMEs to develop new products and services.[…]
MIT-Zuid Subsidy for STENTiT
STENTiT obtains financial support from MKB Innovatiestimulering Topsectoren Zuid-Nederland (MIT-Zuid). This program will provide funds to conduct a technical and economic feasibility study to develop a regenerative stent for children suffering from congenital heart defects. MIT-Zuid is a program in which the 12 Dutch Provinces, the Ministry of Economic affairs and Climate, the Dutch Topsectors[…]
Gerard & Anton Award for STENTiT
During the 5th edition of the Gerard and Anton Awards, STENTiT was selected as one of the top 10 most promising start-up companies to watch 2018. With this award, the jury wants to highlight start-ups in the Brainport region that have the potential to become the next Philips. According to the jury, STENTiT is providing[…]
STENTiT’s Regenerative Stent Approach at PCR Innovators Day Paris 2018.
STENTiT will present at this year’s PCR Innovators Day Paris. In a session dedicated to stents and scaffolds, the managing directors will kick-off the programme with their presentation entitled “Stentit – Regenerative stents – Minimally invasive vascular restoration”, highlighting their innovative technological approach and promising first in-vivo data. The presentation is scheduled for 16:55 CEST[…]
Gold Medal Award for STENTiT in TERMIS European Business Plan Competition
On June 28th, STENTiT was awarded first prize in the TERMIS European Business Plan Competition. After 2 intense pre-selection rounds, 5 out of 19 teams eventually made it to the finals and pitched in Davos, Switzerland. STENTiT was chosen as the winner of the competition due to the quality of the pitch, the technological approach[…]
STENTiT in the Finals of the TERMIS-EU Business Plan Competition 2017!
We are very pleased to announce that STENTiT is one of the 5 finalists of the TERMIS-EU Business Plan Competition 2017. On Tuesday 27th of June around 17:15, we will present our business plan live on stage in room “A Davos” in Davos Switzerland. The winners will be announced later on Thursday June 29th. We[…]
Stentit Pitch At Biomedica 2017
This afternoon, dr. Sol Cabrera and dr. Sanders will present STENTiT during the short company presentation session at Biomedica 2017. In the spirit of euregional and international cooperation, the Biomedica Life Sciences Summit will bring together top researchers, innovators, and entrepreneurs from Belgium, Germany, and the Netherlands, and also from all over the globe. Its[…]
STENTiT Among Top 10 European Candidates In TERMIS BPC
STENTiT is proud to announce that it has been selected among the top 10 European companies to participate in one of the largest start-up competitions in tissue engineering and regenerative medicine across Europe, the TERMIS-EU BPC. TERMIS is the world’s leading non-profit forum for academic and industrial developments within the fields of tissue engineering and[…]
STENTiT Presents at Innovation for Health
STENTiT will present its regenerative stent approach at the Innovation for Health event on the 16th of February in Rotterdam, taking part of the Innovation Pitches afternoon session. Innovation for Health is the Netherlands´ premier conference for key players in Health and Life Sciences. It brings together key players and stakeholders who play decisive parts[…]
STW Take-Off Phase II for STENTiT
The STW Take-Off program has just closed their 5th round. STENTiT is very pleased to announce that its Take-Off Phase II application has been granted. The funding will be used to expand the R&D lines, proceed with translational studies and further grow the business. With this achievement we conclude 2016 which has been a very[…]
STENTiT Wins Investors Forum 2016
During the Dutch Life Sciences conference in Leiden, the founders of STENTiT pitched their business plan to a group of life science investors. Among the candidates, STENTiT was unanimously chosen by the jury as the winner of the Investors Forum. In addition, STENTiT presented the case in front of a large audience during the plenary[…]